MRNA stock forecast, quote, news & analysis
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018... Show more
Moderna (MRNA) Stock Analysis: Pipeline Catalysts Confront a Sharp Valuation Reckoning
Key Takeaways
- Moderna shares closed at $54.07 on July 24, 2026, retreating roughly 9.5% over the trailing 30-day period and approximately 36% below the 52-week high of $85.60 reached on July 6.
- A unanimous 9-0 FDA advisory committee vote supporting the company's mRNA-based seasonal influenza vaccine marks a critical regulatory milestone, with a final FDA decision expected by early August 2026.
- Q2 2026 earnings, scheduled for July 31, are projected to show a dramatic sequential revenue decline to approximately $100 million, underscoring the seasonal nature of COVID-19 vaccine sales.
- Phase III melanoma data for the personalized cancer vaccine candidate mRNA-4157, developed in partnership with Merck (MRK), remains the most significant binary catalyst for the second half of 2026.
- Wall Street maintains a consensus "Hold" rating with an average price target near $49, reflecting persistent skepticism about near-term profitability despite the company's $7.5 billion cash position.
Current Market Snapshot
Moderna shares have experienced a dramatic round-trip over the past several weeks. After surging more than 70% in a single month to hit $85.60 — a 52-week high — on July 6, the stock has since given back the majority of those gains, closing at $54.07 on July 24. The sharp reversal reflects a confluence of profit-taking, valuation concerns, and positioning ahead of what is expected to be a subdued second-quarter earnings report. Year-to-date, MRNA remains up over 90%, far outpacing the broader biotechnology sector as measured by the SPDR S&P Biotech ETF (XBI). However, the stock now trades below its 50-day moving average of approximately $58, a technical threshold that has shifted from support to near-term resistance. Trading volume has also contracted meaningfully from the elevated levels seen during the rally, suggesting that institutional conviction has not kept pace with the earlier price momentum.
Moderna (MRNA) Business Overview and Competitive Position
Moderna is a Cambridge, Massachusetts-based biotechnology company built on messenger RNA (mRNA) technology — a programmable platform that instructs the body's own cells to produce therapeutic proteins. The company gained global prominence through its COVID-19 vaccine Spikevax, which remains the commercial backbone of the business. Today, Moderna fields three approved products and is pursuing a diversified pipeline spanning respiratory vaccines, latent viruses, oncology, and rare genetic diseases. Its RSV vaccine, mRESVIA, secured a four-year procurement agreement with the European Commission covering up to 24 million doses, and the company's mRNA-1010 seasonal influenza candidate is poised for a potential U.S. approval decision. In oncology, the lead program — intismeran autogene, a personalized cancer vaccine developed in collaboration with Merck — is being evaluated in a pivotal Phase III melanoma trial. Moderna's proprietary lipid nanoparticle delivery technology, coupled with a cash and investments position of $7.5 billion as of the first quarter of 2026, provides a durable competitive moat and a lengthy runway to fund pipeline development through the targeted cash-breakeven timeline of 2028.
Recent Developments Driving MRNA
Several high-impact events have shaped Moderna's narrative over the past 30 days. Most prominently, an FDA advisory committee voted 9-0 that the benefits of the company's mRNA-based influenza vaccine outweigh its risks for adults aged 50 and older, setting the stage for a final regulatory decision by August 5. The vote represents a crucial proof point that Moderna's platform can clear regulatory hurdles beyond COVID-19. On the corporate governance front, the company appointed Michael McDonnell — former CFO of Biogen (BIIB) — to its Board of Directors and Audit Committee on July 8, signaling a focus on financial discipline and strategic capital allocation. In early July, the European Commission finalized a contract for mRESVIA, broadening Moderna's commercial footprint beyond the U.S. COVID-19 market. However, analyst sentiment has grown more cautious as the stock's valuation ran ahead of fundamentals: Wolfe Research reiterated an "Underperform" rating with a $25 price target, while even more constructive firms such as Goldman Sachs and RBC Capital raised targets without upgrading their ratings. The looming Q2 earnings report — expected to show just $100 million in revenue and a loss of approximately $1.97 per share — has further tempered enthusiasm, as investors brace for confirmation of the steep seasonal trough in COVID-19 vaccine demand.
Trending AI Robots
For traders seeking data-driven approaches to navigate volatile stocks like Moderna, Tickeron's Trending AI Robots page offers a curated view of top-performing algorithmic trading bots. Tickeron hosts hundreds of AI-powered trading bots that collectively monitor thousands of tickers across multiple asset classes, but only those demonstrating consistent, statistically significant performance appear in this curated section. The bots vary widely in strategy — some focus on short-term technical patterns, others on fundamental or momentum-driven signals — and each bot's performance metrics, trade history, and risk profile are transparently displayed. For investors following biotechnology names where binary catalysts can drive sharp price swings, these AI-driven tools provide an additional lens through which to evaluate opportunities and manage risk. Exploring the Trending AI Robots section can help traders identify which strategies are currently resonating in real market conditions.
2026 Outlook and What Investors Should Watch
Looking ahead, the second half of 2026 presents a series of high-stakes milestones for Moderna. The immediate focus is the FDA's decision on mRNA-1010, expected by August 5; approval would mark the first mRNA-based seasonal flu vaccine in the U.S. market and open a new commercial channel, though meaningful revenue contribution is not anticipated until 2027. The Q2 earnings call on July 31 will provide critical updates on cost-containment progress, cash-burn trajectory, and management's confidence in achieving cash breakeven by 2028. The single most consequential catalyst remains the Phase III INTerpath-001 readout for the personalized melanoma vaccine mRNA-4157 later this year — statistically significant results could fundamentally reshape the investment thesis and validate the broader oncology pipeline. Additional data points, including Phase III updates for the norovirus vaccine candidate mRNA-1403 and pivotal data for the propionic acidemia treatment mRNA-3927, round out a dense calendar of pipeline events. On the risk side, persistent operating losses, dependency on seasonal vaccine uptake, competitive pressure in the respiratory vaccine market, and the wide gap between the current stock price and consensus analyst targets all warrant careful consideration. Investors should also monitor insider activity and institutional positioning for signals about conviction levels heading into this catalyst-rich period.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MRNA in +3.96% Uptrend, advancing for three consecutive days on August 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MRNA advanced for three days, in of 275 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MRNA's RSI Oscillator exited the oversold zone, of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 62 cases where MRNA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRNA as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for MRNA turned negative on July 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .
MRNA moved below its 50-day moving average on July 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MRNA crossed bearishly below the 50-day moving average on July 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MRNA broke above its upper Bollinger Band on July 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MRNA entered a downward trend on August 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.181) is normal, around the industry mean (20.354). P/E Ratio (0.000) is within average values for comparable stocks, (25.057). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.600). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (9.588) is also within normal values, averaging (411.278).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of transformative medicines for patients
Industry Biotechnology